Sialoside-based pattern recognitions discriminating infections from tissue injuries
- PMID: 21208791
- PMCID: PMC3042481
- DOI: 10.1016/j.coi.2010.10.004
Sialoside-based pattern recognitions discriminating infections from tissue injuries
Abstract
Recognition of pathogens-associated molecular patterns (PAMPs) by Toll-like receptors (TLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLR) plays a critical role in protecting host against pathogens. In addition, TLR and NLR also recognize danger-associated molecular patterns (DAMPs) to initiate limited innate immune responses. While innate immune response to DAMPs may be important for tissue repairs and wound healing, it is normally well controlled to avoid autoimmune destruction. Recent data support a role for sialoside-based pattern recognition by members of the Siglec family to attenuate innate immunity. In particular, since CD24-Siglec 10/G interaction selectively dampens host response to DAMPs but not PAMPs, this sialoside-based pattern recognition may serve as a foundation to discriminate PAMPs from DAMPs.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Conflict of interest statement
The authors have no conflict of interest.
Figures
Similar articles
-
CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns.Trends Immunol. 2009 Dec;30(12):557-61. doi: 10.1016/j.it.2009.09.006. Epub 2009 Sep 26. Trends Immunol. 2009. PMID: 19786366 Free PMC article.
-
Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination.Front Cell Infect Microbiol. 2013 Jan 8;2:168. doi: 10.3389/fcimb.2012.00168. eCollection 2012. Front Cell Infect Microbiol. 2013. PMID: 23316484 Free PMC article. Review.
-
The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways.Mol Immunol. 2017 Jun;86:23-37. doi: 10.1016/j.molimm.2017.02.012. Epub 2017 Feb 27. Mol Immunol. 2017. PMID: 28249680 Review.
-
Targeting pattern-recognition receptors to discover new small molecule immune modulators.Eur J Med Chem. 2018 Jan 20;144:82-92. doi: 10.1016/j.ejmech.2017.12.026. Epub 2017 Dec 8. Eur J Med Chem. 2018. PMID: 29268133 Review.
-
PAMPs and DAMPs: signal 0s that spur autophagy and immunity.Immunol Rev. 2012 Sep;249(1):158-75. doi: 10.1111/j.1600-065X.2012.01146.x. Immunol Rev. 2012. PMID: 22889221 Free PMC article. Review.
Cited by
-
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.Cancer Immunol Immunother. 2024 Jan 27;73(2):31. doi: 10.1007/s00262-023-03606-0. Cancer Immunol Immunother. 2024. PMID: 38279998 Free PMC article. Review.
-
Targeting CD24 in Cancer Immunotherapy.Biomedicines. 2023 Nov 27;11(12):3159. doi: 10.3390/biomedicines11123159. Biomedicines. 2023. PMID: 38137380 Free PMC article. Review.
-
The biological roles of CD24 in ovarian cancer: old story, but new tales.Front Immunol. 2023 Jun 9;14:1183285. doi: 10.3389/fimmu.2023.1183285. eCollection 2023. Front Immunol. 2023. PMID: 37359556 Free PMC article. Review.
-
Impact of Siglecs on autoimmune diseases.Mol Aspects Med. 2023 Apr;90:101140. doi: 10.1016/j.mam.2022.101140. Epub 2022 Aug 30. Mol Aspects Med. 2023. PMID: 36055802 Free PMC article. Review.
-
CD24: A Novel Target for Cancer Immunotherapy.J Pers Med. 2022 Jul 28;12(8):1235. doi: 10.3390/jpm12081235. J Pers Med. 2022. PMID: 36013184 Free PMC article. Review.
References
-
- Janeway CA. Approaching the asymptote? Evolution and revolution in immunology; Cold Spring Harb Symp Quant Biol; 1989. pp. 1–13. - PubMed
-
- Janeway CA., Jr The immune system evolved to discriminate infectious nonself from noninfectious self. Immunology today. 1992;13:11–16. - PubMed
-
- Medzhitov R. Approaching the asymptote: 20 years later. Immunity. 2009;30:766–775. - PubMed
-
- Matzinger P. Tolerance, danger, and the extended family. Annual review of immunology. 1994;12:991–1045. - PubMed
-
- Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–1059. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA058033/CA/NCI NIH HHS/United States
- R01 CA058033-17/CA/NCI NIH HHS/United States
- R01 AI064350/AI/NIAID NIH HHS/United States
- R01 AI064350-05/AI/NIAID NIH HHS/United States
- R01 AG036690/AG/NIA NIH HHS/United States
- R01 AI064350-04/AI/NIAID NIH HHS/United States
- R01 CA058033-16A2/CA/NCI NIH HHS/United States
- RC1 GM091648/GM/NIGMS NIH HHS/United States
- R01 CA058033-18/CA/NCI NIH HHS/United States
- R01 AI064350-04S1/AI/NIAID NIH HHS/United States
- RC1 GM091648-01/GM/NIGMS NIH HHS/United States
- R01 AG036690-01A1/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources